NDAINTRAMUSCULAR, SUBCUTANEOUSSOLUTION
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
SYMJEPI (epinephrine) by Fresenius Kabi is adrenergic alpha-agonists [moa]. Approved for anaphylaxis, cardiac arrest. First approved in 2017.
Drug data last refreshed Yesterday
Mechanism of Action
Adrenergic alpha-Agonists
Indications (2)
Clinical Trials (20)
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Started Apr 2026
446 enrolled
Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Started Feb 2026
20 enrolled
Leg Veins
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Started May 2025
238 enrolled
Hypotension During Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Started Apr 2025
186 enrolled
Intraoperative Bradycardia
Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
Started Nov 2024
2,800 enrolled
Septic Shock
Worked on SYMJEPI at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.